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Abstract: Omics data integration is already a reality. However, few omics-based algorithms
show enough predictive ability to be implemented into clinics or public health domains.
Clinical/epidemiological data tend to explain most of the variation of health-related traits, and its joint
modeling with omics data is crucial to increase the algorithm’s predictive ability. Only a small number
of published studies performed a “real” integration of omics and non-omics (OnO) data, mainly to
predict cancer outcomes. Challenges in OnO data integration regard the nature and heterogeneity of
non-omics data, the possibility of integrating large-scale non-omics data with high-throughput omics
data, the relationship between OnO data (i.e., ascertainment bias), the presence of interactions,
the fairness of the models, and the presence of subphenotypes. These challenges demand the
development and application of new analysis strategies to integrate OnO data. In this contribution
we discuss different attempts of OnO data integration in clinical and epidemiological studies. Most of
the reviewed papers considered only one type of omics data set, mainly RNA expression data.
All selected papers incorporated non-omics data in a low-dimensionality fashion. The integrative
strategies used in the identified papers adopted three modeling methods: Independent, conditional,
and joint modeling. This review presents, discusses, and proposes integrative analytical strategies
towards OnO data integration.
Keywords: data integration; omics data; genomics; RNA expression; non-omics data; clinical data;
epidemiological data; challenges; integrative analytics; joint modeling
1. Introduction
Most health-related traits are complex in nature. They result from the interaction of multiple
internal features/alterations with multiple external conditions over a lifespan [1]. Understanding these
complex systems requires modeling exhaustive and appropriate data that characterizes in detail such
features and conditions.
Big data in the biomedical field may refer to different scenarios encompassing large numbers of
clinical (e-medical/e-health records, EMR/EHR) and epidemiological registries (hereinafter, non-omics
data), as well as large biomarker datasets characterizing biological features, such as genomics,
transcriptomics, proteomics, metabolomics, and metagenomics, among others. The latter type of data
are commonly named omics data. While non-omics data are usually obtained through a pre-elaborated
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process done either by the subject when s/he reports on her/his life-style habits or symptoms, or by the
physician/pathologist when s/he evaluates the characteristics of the disease or the tumor, omics data
are generated by high-throughput biotechnological platforms delivering hundreds of thousands of
raw (non-elaborated) variables. Recently, imaging-based high-throughput data is also generated and
named radiomics.
Omics data integration has been addressed in recent years by several important reviews [2–4],
and integrative efforts have been successfully conducted with already available examples of studies
that integrated ≥ 2 different omics sets [5–7]. However, only a few of them resulted in omics-based
algorithms with enough, though still controversial, predictive ability to be implemented into clinics
or public health domains [8,9]. The relatively poor predictive ability of genomic data may partly be
explained by the large variation of health-related traits explained by non-omics data, such as clinical
and epidemiological variables [10]. Therefore, it is crucial to integrate omics and non-omics (OnO) data
in the same models. This provides the opportunity to get insights into biological systems of health and
disease. Unquestionably, this endeavor poses several challenges regarding data generation, capture,
curation, sharing, analysis, visualization, as well as information privacy and storage.
What does OnO data integration mean in the biomedical arena? While it certainly refers to the
inclusion and analysis of these two types of data in the same model/algorithm, several scenarios
can be contemplated according to the number of each considered data type. There is no doubt that
modeling > 1 omics data sets with > 1 non-omics variables falls under this integrative concept.
However, should we consider integration when one omics data set (i.e., genome) is jointly modelled
with only one non-omics variable (i.e., age or tumor stage)? In this scenario, the boundaries of the
integrative picture become blurred and the definition depends on the purpose of the analysis and
whether the inclusion of the non-omics variables aims only to control for a potential confounding effect
or whether its prediction ability is being assessed in combination with the omics data. As a onsequence
of this confusion, the benefit of models including OnO data, is still unclear. This supports the need for
a thorough dissection of the field to diagnose the challenges of the OnO data integrative endeavor and
to identify the analytical strategies to reduce the variability of the study results.
In this review, we focus on the integration of OnO data to investigate complex traits, including
disease risk and prognosis, according to the definition provided above. We first outline and examine
the challenges of integrating the two types of data, we then present the integrative analytical strategies
available, we describe the integrative attempts published in the literature, and we further propose
statistical methods to be used in the analysis of OnO integrative models before concluding.
2. Challenges in Integrating Omics and Non-Omics Data
In this section, we focus mainly on the challenges of OnO data integration which are primarily
related to the nature of both types of data and to the relationship between them, since much attention
has already been paid to the integration challenges of only-omics data in previous reviews [3,4].
2.1. Challenges Due to the Nature of Non-Omics Data
2.1.1. Non-Omics Data Are Complex and Heterogeneously and Subjectively Defined
There is an increasing awareness of the need for standards for non-omics data to integrate them
in both predictive and inference models. Epidemiological data are subject to a survey mode, survey
question standardization, and also context, which may influence data quality and comparability,
and ultimately, the contribution of these variables in the outcome prediction. Standards are yet to be
adopted in epidemiological data generated by different scientists or organizations through different
procedures (i.e., questionnaires) to provide uniformity and consistency in this type of data, which may
help scientists and data analysts to better use, share, and integrate them.
Clinical variables may also be affected by the complexity of their definition. A tumor stage,
for instance, results from a combination of pathology and imaging information. Regarding clinical
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standardization, there are some initiatives as CDISC (Clinical Data Interchange Standards Consortium,
http://www.cdisc.org) that harmonizes definitions and develops standards across the clinical space
(i.e., the Study Data Tabulation Model (SDTM) and the Analysis Data Model (ADaM)) to enable
information systems’ interoperability to improve medical research and related areas of healthcare.
Another important challenge relates to the nature of the aforementioned types of non-omics data,
because they are subjective assessments that result from a complex elaboration process based on skills
and previous knowledge of the evaluator which may lead to reporting biases (i.e., grading/staging,
clinical decisions, or reporting past occupational exposures). In this regard, non-omics assessments
totally differ from omics variables that are completely homogeneous and standardized data within the
same data set. Integrating these different types of data poses challenges in the analytics strategy since
the transformation or weighting of data may be required.
2.1.2. Heterogeneity Across Non-Omics Data
The lack of uniformity of non-omics data, including qualitative and quantitative variables
measured with different scales even to characterize a unique trait/exposure, also limits their integration
in an OnO model to predict the outcome of interest and imposes both a conceptual challenge and
a hurdle in practical data analysis. Moreover, data transformation (i.e., integrating variables with
zero values) and data normalization procedures may be necessary prior to integration analysis,
to avoid getting biased parameter estimates when the normality assumption required by some methods
is violated.
2.1.3. Large Scale Non-Omics Data
To date, the inclusion of non-omics data into integrative prediction models has been at a low
dimension. However, the hype generated by so-called Big Data has also affected the healthcare
industry. The advent of Big Data in the clinical setting has increased by the availability of EHRs
(e-health records), unstructured medical text, and image data. These “large in scale, high in dimension”
non-omics data, along with the design of well-characterized large and longitudinal epidemiological
studies at an unprecedented scale, has led to the need for the integration of high dimension non-omics
data in models. The use of other digital data sources coming from different wearable devices, such
as smart watches, wristbands or wearable health equipment, are also expected to revolutionize
epidemiology. The availability of longitudinal data concerning vital signs or environmental variables
is expected to shed light on the knowledge of disease dynamics [11]. In addition to the high volume of
data, other challenges of using digital epidemiology data are related to the collection, mining, access
(i.e., limited and costly access), and data sharing (i.e., variability in definition/standardization of
variables and subjective filters applied to the raw data which are needed to analyze those data).
The high dimensionality in non-omics data also implies the presence of (1) correlation structure
between these variables, (2) large scale longitudinal data, (3) data sparseness (i.e., medications,
laboratory or diagnosis tests), and (4) data missingness, which in contrast to omics data, are not
independent on the participating individuals. In this regard, multi-dimensional approaches need
samples with all the OnO data measured in the same individuals. All of these aspects must be taken
into account in integration models.
Moreover, the advent of using EHRs will also be challenging in processing both objective and
subjective traits, as well as structured and unstructured data. Subjective traits were defined by Jette
as phenotypes that the “physician cannot assess directly with confidence and have to rely on patient
(i.e., pain, physical, social, and emotional function) [12]. On the contrary, objective outcomes are those
which the “physician can assess directly with confidence” [13]. Unstructured data, as the physician
notes, which are in many cases embedded within semi-structured EHR data, are the most frequent
data in the medical records. Although they have been mostly ignored, they are needed to understand
the whole of a patient, and it will be needed to process and utilize them.
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2.2. Challenges Due to the Relationship between Non-Omics and Omics Data
2.2.1. Ascertainment Bias
In a case-control design, the integration of OnO data may be affected by the presence of
ascertainment bias. In this type of epidemiological design, individuals are enriched for the risk factors of
the study. If omics data are generated on the basis of the subject’s exposure, ascertainment could induce
additional correlation between all OnO data [14]. It is known that omics profiles are not independent
of demographic factors [15]. For example, age and gender may be associated with DNA methylation
values [16,17]. In the clinical setting, genomic variables may be correlated with clinical variables due
to population stratification [18]. Furthermore, when survival is the outcome, an insufficient clinical
follow-up and the larger incompleteness affecting the clinical variables, in contrast to the completeness
of high-throughput molecular data, may bias the effect estimates of the remaining clinical variables
in a greater manner than their counterparts of omics variables. On the contrary, traits identified
from an observational resource, such as medical records, may also be subject to the presence of
ascertainment bias, since the probability that a particular phenotype is recorded is not uniform across
patients or diseases.
2.2.2. Interactions between Omics and Non-Omics Data
In order to understand the underlying mechanisms of the disease of interest, it is important
to consider the combined interactions between the factors included in the model, irrespectively of
their nature (omics vs. non-omics). The interaction between data types can be complex as well:
gene expression changes may imply phenotypic abnormalities, and this results in a more complex
relationship between molecular and clinical data.
2.3. Other Challenges
2.3.1. Fairness
According to Van de Geer, a fair model is a model where all variable blocks, each block
representing a set of variables sharing similar characteristics, contribute equally, in contrast to a model
dominated by only a few of the different sets [19]. In OnO integrative modeling, should each variable or
block contribute equally to the outcome? How can we prevent clinical variables from being penalized
when combined with a high-throughput dataset?
2.3.2. Presence of Subphenotypes
The consideration of heterogeneous phenotypes in the model may also add complexity to the
OnO model definition. However, ignoring the presence of subphenotypes may affect the performance
of the OnO model [20].
3. Integrative Analytical Strategies
The strategies for building hybrid models that contain both omics and non-omics data can be
classified as: Independent modelling, conditional modelling, and joint modelling (Figure 1). While the
joint modeling strategy is the most proper integrative approach, independent and conditional modeling
are also commonly used approaches to jointly model OnO data.
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established risk or prognostic score/factors identified and reported in previous efforts. In parallel, the 
omics variables are selected by considering a model only including omics variables. Both modelling 
processes typically require variable selection or dimension reduction. The independently selected 
omics and non-omics variables are then combined in a final model. The predictive accuracy of the 
combined model is compared with that of the non-omics data model. 
Although independent modeling is the simplest integrative approach and, probably, the most 
common strategy for combining OnO data, this approach cannot capture the correlation/interaction 
structure of the datasets of different natures. To overcome this limitation, Nevins et al. [22] and 
Pittman et al. [23] proposed tree-based approaches to combine clinical and molecular scores in such 
a way possible interactions among OnO data are considered. Whether this approach is also applicable 
to omics data should be elucidated. Another caveat of the independent modeling strategy is that the 
predictive power of omics data tends to be overestimated since the trait is also used in the feature 
selection process. 
3.2. Conditional Modeling Approach 
This strategy consists in first defining a clinical model with non-omics variables and second, 
adding omics variables to the already built non-omics model. In other words, in the conditional 
modelling approach, the selection of omics variables is performed by considering a model that 
contains or adjusts for the previously selected clinical/epidemiological covariates. The key point of 
this conditional modeling approach is to decide which omics variables should be added to the clinical 
model. There are different ways to implement this strategy, the simplest one, though not 
recommended, is univariate selection, where each omics variable is tested individually and added to 
the clinical model if there is an increase in the prediction accuracy. As discussed in Bovelstad et al. 
[24], univariate selection performs poorly, usually yielding worse predictions than the clinical model 
approach. A more powerful strategy is to perform partial dimension reduction, which consists in 
considering the joint model with all omics and clinical variables and applies a dimension reduction 
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3.1. Independent Modeling Approach
This strategy, also known as late integration, implies that both the omics and the non-omics
data models are built independently [21]. The non-omics data model is built independently of the
omics variables by fitting a model that only includes clinical/epidemiological variables or already
well-established risk or prognostic score/factors identified and reported in previous efforts. In parallel,
the omics variables are selected by considering a model only including omics variables. Both modelling
processes typically require variable selection or dimension reduction. The independently selected
omics and non-omics variables are then combined in a final model. The predictive accuracy of the
combined model is compared with that of the non-omics data model.
Although independent modeling is the simplest integrative approach and, probably, the most
common strategy for combining OnO data, this approach cannot capture the correlation/interaction
structure of the datasets of different natures. To overcome this limitation, Nevins et al. [22] and
Pittman et al. [23] proposed tree-based approaches to combine clinical and molecular scores in such
a way possible interactions among OnO data are considered. Whether this approach is also applicable
to omics data should be elucidated. Another caveat of the independent modeling strategy is that the
predictive power of omics data tends to be overestimated since the trait is also used in the feature
selection process.
3.2. Conditional Modeling Approach
This strategy consists in first defining a clinical model with non-omics variables and second,
adding omics variables to the already built non-omics model. In other words, in the conditional
modelling approach, the selection of omics variables is performed by considering a model that
contains or adjusts for the previously selected clinical/epidemiological covariates. The key point
of this conditional modeling approach is to decide which omics variables should be added to the
clinical model. There are different ways to implement this strategy, the simplest one, though not
recommended, is univariate selection, where each omics variable is tested individually and added to
the clinical model if there is an increase in the prediction accuracy. As discussed in Bovelstad et al. [24],
univariate selection performs poorly, usually yielding worse predictions than the clinical model
approach. A more powerful strategy is to perform partial dimension reduction, which consists in
considering the joint model with all omics and clinical variables and applies a dimension reduction
process only to omics variables. One of such dimension reduction approach is least squares-partial
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least squares (LS-PLS) [25]. The major caveat of this method is that it suffers from convergence
problems, and its performance also depends on the level of collinearity between the two types of data.
Alternative approaches to LS-PLS, when the outcome is binary, are partial least square regression [26],
ridge regression [27], and LASSO [28] performing dimensionality reduction only on omics data [24].
Other approaches for time dependent variables are described in [29,30]. Binder et al. proposed
the algorithm CoxBoost which implements Cox penalized regression that allows some covariates
(clinical variables) to be unpenalized [29] and Li et al. applied partial dimension reduction of the
supergenes identified after estimating principal components with the omics variables, meanwhile
considering the clinical covariates [30]. A common drawback of all the above methods is that they are
computationally intensive.
3.3. Joint Modeling Approach
Under this strategy, omics and non-omics data are jointly modelled in a supervised or
unsupervised manner. While there is a growing body of articles on multi-marker and multi-omics data
integration [2,4,7,20,31,32], the literature that explicitly addresses how to integrate omics and non-omics
data in a joint modeling approach is scarce. Following Ritchie’s suggestion [3], we can further classify
the joint modeling approaches of OnO data into multi-staged (i.e., separate analysis of the associations
between the different data types and subsequently with the outcome of interest) and meta-dimensional
analyses (i.e., simultaneous analysis of the different data types). One of the first examples of
a meta-dimensional approach is the study by Sun et al. that performs concatenation-based integration
and joint variable selection of both OnO data using the i-relief algorithm [33]. Those classified as
meta-dimensional analyses were further classified into three groups as concatenation-based integration,
transformation-based integration, and model-based integration.
4. Attempts of OnO Data Integration in Clinical and Epidemiological Studies
We searched the PubMed electronic database using keywords to identify studies integrating OnO
data towards their association with or prediction of the trait of interest, as well as to evaluate their joint
classification performance. The search strategy included a combination of keywords related to omics,
non-omics, and data integration, for the period 1 December 2009 to 1 October 2018. The logic terms
used were: ((integration AND (risk OR score OR prediction OR prognosis) AND (epidemiological OR
clinical OR environmental OR exposure) AND (genomic OR GWAS OR genetic OR transcriptomics
OR proteomics OR metabolomics OR gene expression OR epigenomics OR epigenetic OR microbiome
OR metagenomics))).
The search strategy generated 1,634 records. In this review, we only considered those articles
integrating non-omics and high-throughput generated omics data sets in the modeling of the
disease/trait as defined in the Introduction. The search resulted in a total of 16 studies almost all
of them belonging to the cancer research area (see Table 1). We were first surprised by the small
number of published studies at present that performed a “true” integration of OnO data. Although
this contribution does not intend to be a systematic review, we consider that the identified papers
constitute a representative sample of the attempts done in the field up to date. Hereinafter, we describe
the objectives of the OnO integration, the outcomes and the OnO data types considered in the models,
as well as the integrative analytical strategies applied in the selected papers (Table 1).
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Table 1. Main features of the identified studies conducting omics and non-omics data integration.
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Table 1. Cont.
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Table 1. Cont.
Reference Title Outcome Big Data: Omics andImage Data Non-Omics Objective Model Performance Approach
[46]
Integrating Clinical and
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Lauren classification (STAD)






Ovarian and HNSC f:
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CNS: Central Nervous System; ER: Estrogen receptor; NPI: Nottingham Prognostic Index; NB2004: German neuroblastoma trial; OS: Overall Survival; AML: Acute myeloid leukaemia; CT:
Chemotherapy; RT: Radiotherapy; CT: Chemotherapy; TSG: Tumor stage and grade; PRS: Polygenic risk score; HNSC: Head and neck squamous cell carcinoma; DLBCL: Diffuse large
B-cell lymphoma; IBS: Integrated Brier score. a Models performance in the largest datasets. b It corresponds to the AUC of COV+GE+GExHT model. c No improvement in classification
performance was also obtained in TP. d We provide only the results for OS, when no external validation was considered. Similar performances were obtained when the external validation
was performed. e Performance of M2EFM Meth+Exp model. f We report the C-index results for the cancers where the largest prognostic power was achieved.
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4.1. Study Objective
All selected papers aimed to evaluate the prediction performance of the OnO integrative models.
4.2. Study Outcome
Garali et al. identified OnO variables discriminating cases with spinocerebral ataxia from
controls [37]. Only two out the 16 selected studies integrated OnO data to predict the risk of skin [45],
and bladder [40] cancers. The rest of papers integrating OnO data analyzed cancer outcomes. Among
the cancers analyzed were breast [24,35,38,41,43,44], central nervous system [24,25,34], liver [36],
hematological [24], melanoma [39], bladder [20], kidney [42], and several cancers [46]. Six studies
integrated both data types to evaluate the ability to predict the survival time [24,35,36,42,43,46].
Four studies transformed the survival time into a binary outcome (i.e., survival at a given
time) [35,39,41,44]. López de Maturana et al. [20] transformed each time to event into several binary
outcomes by accounting for censoring and time. Two studies analyzed the logarithm of survival time
also accounting for censoring [34,38] . And two studies assessed the treatment prediction response as
a categorical variable: Responders vs. non-responders [25,43].
4.3. Omics Data
Most of the papers only integrated one type of omics data [20,24,25,36,40,43–45]; five papers
integrated two omics data types [35,38,41–43]; and four papers integrated > 2 omics
data [34,36,39,46]. Gene expression data was the most commonly used high-dimensional omics
data [24,25,34–36,38,39,42–44,46] followed by copy number alterations (CNA) [25,34,35,38,41,46],
and SNPs [20,34,40,45,46]. Methylation data was considered by five selected papers [34,36,42,43,46] and
three studies integrated microRNA (miRNA) data [36,39,46]. Only Jayawardana et al. [39] integrated
protein expression data and Garali et al. [37] integrated 754 metabolite biomarkers in a predictive
model. In those studies that integrated > 1 omics data set, gene expression was the most informative
type in terms of prognostic utility [39,46], followed by microRNAs, and DNA methylation profiles [46].
4.4. Non-Omics Data
All the selected papers incorporated the non-omics data in a low-dimensionality fashion,
meaning that only a few variables were integrated in the models. Non-omics information was a quite
heterogeneous group of data formed by both categorical and continuous variables. The majority of
non-omics data were clinico-pathological variables, including treatment, tumor stage, tumor size,
lymph status, histological type, estrogen receptor status, progesterone receptor status or human
epidermal growth factor receptor (see Table 1 for further details). Specific tumor scales, such as
Breslow thickness and Clark’s level in melanoma [39] or classifications as Lauren classification in
stomach adenocarcinoma [46] or the international prognostic index in lymphoma [24] were also
used as non-omics clinico-pathological variables. Moreover, cancer subtype definition based on
gene-expression signatures as PAM50 signature for breast cancer [42,43,46] as well as Mammaprint [46]
were also considered. Jayawardana et al. were the only ones integrating metabolic imaging obtained
by magnetic resonance spectroscopy, along with pons volume [39]. In addition, demographical
data as age, gender, ethnicity, or region were also considered. Smoking status was the only
epidemiological/life-style variable included in the risk models [40]. None of the papers considered
large scale clinical or epidemiological data in their models.
4.5. Integrative Analytical Strategies
The integrative strategies used in the identified papers adopted the three different modeling
methods described before (see Table 1): (1) Independent modeling, (2) conditional modeling, and
(3) joint modeling, which were implemented using one-step or two-step designs. The published
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studies applied these methods assuming low-dimensional non-omics data, while omics data were high
dimensional and required some variable selection, dimension reduction, or regularization process.
Examples applying the independent modeling approach are found in [36,39,42–44,46].
Thompson and Marsit [42], combined both multistage and meta-dimensional elements in
a Methylation-to-Expression Feature Model (M2EFM) by first defining a molecular score that combined
DNA methylation and gene expression and then performing a second regression to integrate clinical
variables in a prognostic model for clear cell kidney cancer. van Vliet et al. [44] determined the
optimal sets of features from each data type separately by using different classifiers such as the
nearest mean, the simple Bayes, the 3-Nearest-Neighbor, the support vector machine, and the Tree
Classifier. They then used these sets of features and all training samples in the final integrative
model. Jayawardana et al. [39] used multiple types of omics data (i.e., microRNA, mRNA and protein
expression) to integrate them with clinico-pathological variables also using an independent modeling
approach. Briefly, they selected an optimized set of omics features integrated as a molecular signature
of each data type (known as pre-validated vector) and then modelled them in combination with the
clinico-pathological data, creating a combined prognostic signature. Chaudhary et al. [36] applied
a transformation-based integration of multi-omics data independently from the clinical variables by
using a deep-learning approach to integrate RNA-seq, miRNA-seq, and DNA methylation data to
identify subgroups of hepatocellular carcinoma. Zhu et al. [46] did similarly, which led to substantially
improved prognostic performance over the use of clinical variables alone in half of the cancer types
examined. Particularly, they used the kernel-fusion Cox model as the multi-omics kernel learning
method for prognostic prediction. Their approach consisted of three steps: (1) They built a kernel
reflecting the similarity of the individuals based on each omics data including mRNA, miRNA, CNA,
methylation and mutational status; (2) they applied a kernel alignment approach to evaluate whether
the similarity matrix built using an omics data set aligned well with its counterpart defined by another
omics data type; and (3) they evaluated the prognostic performance of the molecular profile of each
individual, which was assumed to follow a multivariate normal distribution with mean zero and
(co)variance matrix K corresponding to a fused kernel. This resulted from the linear combination or
fusion of each omics similarity matrices (somatic mutation, mRNA, miRNA, methylation, and copy
number profiles), along with the clinical prognostic score and the polygenic risk score based on odds
ratios reported in the literature. Through this way, prognosis-relevant signals from multiple pathways
and involving a large number of omics biomarkers became visible only when aggregated. Zhu et al.
applied, by far, the most comprehensive integrative approach [46].
Two studies applied the conditional modeling approach. Bazzoli and Lambert-Lacroix [25]
adopted it using a one-step approach. They adapted the Least Squares—Partial Least Squares (LS-PLS)
procedure to accommodate logistic regression hybrid models resulting into three different approaches:
LS-PLS-IRLS (where IRLS denotes Iteratively Reweighted Least Squares algorithm), R-LS-PLS, and
IR-LS-PLS differing in the way PLS is used in the classification context. The three approaches involved
the incorporation of PLS scores resulting from the application of PLS regression on omics data into
the OLS equations in an iterative way to obtain a one-step hybrid model accommodating OnO data.
Bovelstad et al. [24] proposed a Cox regression model including OnO variables and applying different
methods for dimensionality reduction only to omics data and found that the improvement of the OnO
model varied among diseases: Whereas large improvements were obtained when OnO model was
applied to diffuse large B-cell lymphoma (DLBCL) and neuroblastoma datasets, similar performance
was obtained using gene expression data only vs. the integrative model.
Joint modeling integration was the most commonly used approach by the identified studies.
Particularly, the majority of the studies applied the transformation-based meta-dimensional analysis,
which combined multiple data sets after transforming each data type into an intermediate form,
such as a graph or a kernel matrix. Three studies applied Bayesian Reproducing Kernel Hilbert spaces
regressions as a modeling framework able to incorporate clinical risk factors and high-dimensional
omics profiles [34,38,45], González-Reymúndez et al. also assessed the interactions between OnO
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factors [38]. Seoane et al. proposed a multiple kernel learning strategy implementing feature selection
separately for each data type and by pathway membership [41]. Examples of the concatenation-based
integration meta-dimensional analyses are found in [20,24,35,40,44]. Boulesteix et al. [35] applied
the IPF-LASSO, a penalized regression method that allows different penalty terms to the different
layers of information, whereas López de Maturana et al. [20,40] implemented a Bayesian LASSO
coupled threshold modeling with different priors imposed for OnO data. Bovelstad et al. [24] proposed
a Cox regression model including OnO variables and applying different methods for dimensionality
reduction only to omics data. Van Vliet et al. [44] applied five classifiers (nearest mean, the simple
Bayes, the 3-nearest-neighbor, the support vector machine, and the tree classifier) concatenating the
omics and clinical features.
In addition, Garali et al. implemented a regularized generalized canonical correlation analysis
(RGCCA) and a sparse generalized canonical correlation analysis (SGCCA) model-based integration
approaches, in which each data type is analyzed separately and then combined in a final integrative
model [37]. Rather than operating sequentially on parts of the measurements, this integrative approach
aims at summarizing the relevant information between and within blocks of variables. Particularly,
RGCCA incorporates a variable selection procedure and SGCCA allows both the extraction of
biomarkers and the reduction of the multiblock datasets into a few meaningful components.
4.6. OnO Data Integrative Models Performance
The performance of the models considered in the selected papers was retrieved, whenever
provided, and is displayed in Table 1. In general, the selected papers showed that the OnO data
integrative models perform better in terms of classification performance than the only-clinical/
epidemiological or only-omics model [24,25,34,38,39,41–44,46]. However, there were studies
reporting no/slight improvement in terms of classification performance of OnO data integrative
models [20,24,36,40,46]. The variability in terms of predictive improvement observed when
applying OnO modeling could depend on different factors, such as the outcome, the omics
and clinical/epidemiological variables, and the integrative method implemented. For example,
Bovelstad et al. [24] found that the improvement of OnO model varied among diseases: While large
model performance improvements were obtained when OnO data integration was applied to DLBCL
and neuroblastoma datasets, no gain in performance was observed when gene expression data was
integrated with clinic-pathological variables in the breast cancer dataset. Furthermore, the SNPs
performed poorly in the outcome prediction across cancer types [20,40,46].
5. Recommended Integration Strategies
As previously discussed, we distinguished three different strategies for building hybrid models
containing both omics and non-omics data: Independent modeling, conditional modeling, and joint
modeling. Selected papers have applied these approaches to the integration of low-dimensional
non-omics data and high dimensional omics data, which requires some variable selection,
dimensionality reduction or regularization process before or during their modeling. However, these
integrative modeling strategies also apply to high dimensional non-omics data, a scenario that is
becoming more frequent because of new technological advances that constantly increase our capacity
for obtaining additional information from many different sources (e.g., EHRs or wearable sensors).
Joint modeling approaches, where omics and non-omics data are jointly modelled in a supervised
or unsupervised manner, are those recommended to integrate both large-scale OnO data, because they
account for the correlation structure between the two data types and capture a larger complexity than
the conditional or independent modeling. The decision of which modeling strategy (multi-staged or
meta-dimensional) to follow should be done in accordance with the main objective of the analysis:
Association testing or risk prediction [47]. Multi-staged analysis that models the relationship between
the different layers of information will probably be preferable when the interest is to increase our
biological knowledge of the disease mechanisms. On the other hand, the meta-dimensional approach
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will be more suitable when the goal is to improve prediction or prognosis for personalized medicine
and modeling the mechanisms is not so relevant, although they are not exclusive for these purposes.
Concatenation-based integration combines the different data types into a joint data matrix and performs
a variable selection or dimension reduction to the whole data set. The concatenation approach cannot
ignore that the different data types are expected to have different relevance to the outcome and the
joint analysis should take this into account.
In addition to the methods used by the identified studies described previously, the following
modeling strategies could be considered in jointly modeling OnO data. The kernel-fusion Cox model
used in Zhu et al. [46] initially designed as multi-omics kernel learning method could be extended
to include also non-omics data in a kernel reflecting also the similarity between the profiles for each
multimodal data. iCluster and iCluster2 are examples of a model-based integration strategy and could
also accommodate non-omics variables [6,48]. Briefly, they perform a joint latent variable model-based
clustering method, where the latent component connects the different data specific models, inducing
dependencies across the different data types. Furthermore, deep-learning methods could also be
used in a model-based integrative approach [49,50]. Another machine learning approach, the tensor
factorization, allows the integration of multiple data modalities and supports dimensionality reduction
and identification of latent groups [51]. A tensor factorization is a multidimensional array where each
modality spans one axis and helps identifying group-wise interaction. Since it is an unsupervised
method, it may be used to identify phenotypes, as it has been done in the Multi-Ethnic Study of
Atherosclerosis (MESA) for discovering subgroups of heart failure patients. A drawback of this method
is the interpretability of the results.
6. Concluding Remarks
Disentangling a complex trait requires not only the understanding of its “complex” biological
system but also the combinatorial effects of other factors (i.e., host-related, environmental,
socio-economics, etc.). The integration of OnO data can lead to finding new risk factors of
a disease, propose better predictive models, distinguish patients with favorable response to treatment,
and therefore help in the future of personalized medicine [52]. Unfortunately, OnO data integrative
efforts are still scarce, although they are expected to become more frequent because of the advent of
Big Data in the medical field.
In general, integrating both molecular and clinical data results in better prognostic models than
either type alone as has been shown by several authors [39,43,44,46]. Possible explanations are that
individual classifiers collect associations with the outcome of interest and their redundancy leads
to a better prediction; that the clinical set of features adds some additional information which is
not captured by the omics data; and that relevant signals may come from multiple pathways and
involve a large number of omics biomarkers, the effect of which may be visible only when aggregated.
However, model improvement has not always been observed when OnO data is integrated [36,40].
In any case, exploring OnO data integration becomes a must in the biomedical field. It requires
method development, validation, and standardization. This review represents an endeavor towards
these aims by identifying the challenges that OnO data integration presents, as well as discussing and
proposing integrative analytical strategies. We hope it guides OnO data integrative efforts.
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